Cancer patients get fairer drug costs under new insurance parity rule
S. 5004 — Cancer Drug Parity Act of 2026 · Filed by Tina Smith (D-MN) · 1 cosponsor · Introduced Jul 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires health insurance plans to charge patients the same out-of-pocket costs (copays, deductibles, coinsurance) for oral cancer drugs taken at home as they do for intravenous cancer drugs administered in a doctor's office. It prevents insurers from raising costs on oral drugs or adding new restrictions to comply with this rule, and it requires a government study within two years to measure whether the law reduces patient costs.
Why we flagged it
The bill's core function is to equalize out-of-pocket costs for oral versus intravenous cancer drugs in employer health plans. It is a consumer-protection measure targeting cost-sharing disparity, not a subsidy or deregulation.
What the text implies
- Oral cancer drugs may become more attractive to patients due to lower cost-sharing, potentially shifting demand away from intravenous formulations and affecting infusion center utilization and revenue.
- Insurers may respond by raising baseline cost-sharing on ALL cancer drugs (oral and IV) to offset the parity requirement, potentially harming patients if the law does not prevent such across-the-board increases.
The full analysis lists 4 implications of this text.
Who stands to gain
oral anticancer drug manufacturers; patients with employer-sponsored health insurance